Brexpiprazole: A New Treatment Option for Schizophrenia

Conclusion Schizophrenia is a debilitating condition with significant morbidity and mortality. Many atypical antipsychotics improve functioning, but they carry risks for adverse effects. Brexpiprazole reduced symptoms of acute schizophrenia and prevented relapse with minimal adverse effects. It is an additional option for clinicians who treat patients with schizophrenia, and ongoing trials are assessing its efficacy as an adjunctive treatment for patients with posttraumatic stress disorder or behavioral disturbances associated with dementia. Disclaimer The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Acknowledgment The author is grateful to Kathy Thomas for her assistance in locating references. References 1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. 2. American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Press Inc.; 2013:87–122. 3. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007;68 Suppl 4:4–7. 4. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–179....
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Drug Development Psychiatry Psychopharmacology Review Schizophrenia antipsychotic brexpiprazole Source Type: research